Vera started at buy by Goldman Sachs, atacicept potential cited
Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment bank ...
Vera Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent ...